Loading
KRT-232 is an experimental small-molecule drug from Kartos Therapeutics in phase 2 trials for myeloproliferative neoplasms, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia, aimed at MDM2 and TP53.
KRT-232 is a small-molecule drug developed by Kartos Therapeutics. Its targets are MDM2 and TP53 (the sponsor names MDM2-p53 interaction). The sponsor states: A novel, potent and selective oral MDM2 inhibitor, referred to on the current site as navtemadlin. ClinicalTrials.gov describes the intervention as: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in myeloproliferative neoplasms, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and hodgkin lymphoma. The largest, NCT04502394, plans to enrol 84 participants with primary completion was scheduled for 2022-10 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A novel, potent and selective oral MDM2 inhibitor, referred to on the current site as navtemadlin. Connects to MDM2 and TP53.
1.KRT-232 slips into a pocket on MDM2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"KRT-232" OR ABSTRACT:"KRT-232") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KRT-232, not a curated reading list.
Shares Chronic lymphocytic leukaemia, Hodgkin lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Hodgkin lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
Shares MDM2 and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Hodgkin lymphoma and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Hodgkin lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.